VY
Veeraiah Yellavula
About Veeraiah Yellavula
Data last updated:
Veeraiah Yellavula is a Director at Alfansa Bio Private Limited (since 2017). The companies operate in Pharma and Chemicals. Alfansa Bio Private Limited reported revenue of ₹1.34 Cr (FY 2025). Earlier, Veeraiah Yellavula was a Director at Glatrix Biotech Private Limited (2022–2024).
Current companies
| Company | Designation | Appointment | Founded | Revenue | Status |
|---|---|---|---|---|---|
 Alfansa Bio Private Limited U74999TG2017PTC117252 | Director | 22 May 2017 | 2017 | ₹1.34 Cr (FY 2025) | Active |
Previous companies
| Company | Designation | Appointment | Founded | Revenue | Status |
|---|---|---|---|---|---|
| Glatrix Biotech Private Limited U24230TG2022PTC162268 | Director | 02 May 2022 | 2022 | ₹18.7 Lakh (FY 2024) | Active |
Explore Director's current and past company associations Uncover their professional journey today!
Board colleagues of Veeraiah Yellavula
| Name | DIN | Company | Designation |
|---|---|---|---|
| Yellavula Sreevani | 07496619 | Alfansa Bio Private Limited | Director |
Directorship timeline
Open interactive timeline →Shareholding and investment profile for Veeraiah Yellavula
Company-level share counts, filed values, and quarterly changes require authenticated premium access.
- Company-level holdings
- Filed share counts
- Reported values
- Quarterly changes
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Veeraiah Yellavula
Veeraiah Yellavula currently holds 1 directorship: Alfansa Bio Private Limited (Director, since 22 May 2017, revenue ₹1.34 Cr (FY 2025)).
Veeraiah Yellavula was first appointed on 22 May 2017 as Director at Alfansa Bio Private Limited. The most recent appointment on record is 02 May 2022 at Glatrix Biotech Private Limited.
Veeraiah Yellavula held 1 earlier board appointment: Glatrix Biotech Private Limited (Director, 02 May 2022 to 29 Jun 2024).
The current boards of Veeraiah Yellavula's companies include Yellavula Sreevani (Alfansa Bio Private Limited).